<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01738542</url>
  </required_header>
  <id_info>
    <org_study_id>NTC25102012</org_study_id>
    <secondary_id>E.C.13/2009.CEIC10</secondary_id>
    <nct_id>NCT01738542</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Bosentan for Intermittent Claudication in Peripheral Arterial Disease</brief_title>
  <acronym>CLAU</acronym>
  <official_title>CLAU Test Results (CLinical Assessment And Endothelin fUnction Assessment After Endothelin Receptor Antagonist) : Randomized Controlled Clinical Trial of Bosentan for Intermittent Claudication in Peripheral Arterial Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Getafe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Getafe</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective study, proof-of concept, randomized, controlled, parallel groups, simple blind
      was performed in 30 male patients (50-60 years old) with Intermittent Claudication
      (Rutherford category 1-2) recently diagnosed and clinical manifestations not exceeding 6
      months with hypertension and/or dyslipidemia as unique co-morbility disorders. After a period
      of stabilization of the claudication distance in the Stress test (12.5%, 3.2 km/h) during 2
      weeks, were randomized 1:1 to the experimental arm (Bosentan 62.5 mg twice daily/four weeks
      and 125 mg twice daily/eight weeks) or control group.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Absolute Claudication Distance (ACD) respect baseline values</measure>
    <time_frame>1 Year</time_frame>
    <description>To determine the efficacy of bosentan on the improvement in the absolute claudication distance in the exercise in patients with Intermittent Claudication due Peripheral Arterial Disease.
ACD and percentage of change, both for the treatment group and control group, at each visit after baseline : 1 month, 3 months, 6 months and 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in flow-mediated arterial dilation (FMAD) respect baseline values</measure>
    <time_frame>1 Year</time_frame>
    <description>To determine the efficacy of bosentan on the improvement in the overall endothelin function in patients with Intermittent Claudication due Peripheral Arterial Disease
FMAD for the treatment group and control group, at each visit after baseline : 1 month, 3 months, 6 months and 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Analytical plasma values at each visit respect baseline values</measure>
    <time_frame>1 Year</time_frame>
    <description>Safety of Bosentan in patients with Intermittent Claudication due Peripheral Arterial Disease.
Analytical values : plasma electrolyte values, hepatic function, renal function, coagulation profiles, peripheral blood cell count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the ankle brachial index (ABI) respect baseline values</measure>
    <time_frame>1 Year</time_frame>
    <description>Efficacy of bosentan on the improvement in the hemodynamic states in patients with Intermittent Claudication due Peripheral Arterial Disease.
ABI for the treatment group and control group, at each visit after baseline : 1 month, 3 months, 6 months and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in subjective claudication distance (SCD) reported by the patient, as is defined in the Walking Impairment Questionnaire (WIQ), respect baseline values</measure>
    <time_frame>1 Year</time_frame>
    <description>Efficacy of bosentan on the improvement of functional status (symptoms of claudication) in patients with Intermittent Claudication due Peripheral Arterial Disease
SCD for the treatment group and control group, at each visit after baseline : 1 month, 3 months, 6 months and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Adverse events during the study</measure>
    <time_frame>1 Year</time_frame>
    <description>Safety of Bosentan in patients with Intermittent Claudication due Peripheral Arterial Disease.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in the serum levels of Endothelin (ET) respect baseline values</measure>
    <time_frame>1 Year</time_frame>
    <description>To determine the efficacy of bosentan on the improvement in the endothelin function in patients with Intermittent Claudication due Peripheral Arterial Disease</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in the serum levels of C-reactive protein (CRP) respect baseline values</measure>
    <time_frame>1 Year</time_frame>
    <description>To determine the efficacy of bosentan on the improvement in inflammatory status in patients with Intermittent Claudication due Peripheral Arterial Disease.
CRP for the treatment group and control group, at each visit after baseline : 1 month, 3 months, 6 months and 12 months</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Antiaggregants &amp; Statins &amp; Antihypertensives &amp; Bosentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bosentan 62.5 mg/12 hours (first four weeks) and 125 mg/12 hours (eight weeks) plus Antiaggregant therapy (AAS 100mg/d or Clopidogrel 75mg/d), Statins and Antihypertensive therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antiaggregants &amp; Statins &amp; Antihypertensives</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Antiaggregant therapy (AAS 100 mg/d or Clopidogrel 75 mg/d), Statins, Antihypertensive therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosentan</intervention_name>
    <description>Bosentan 62.5 mg/12 hours (first four weeks) and 125 mg/12 hours (eight weeks)</description>
    <arm_group_label>Antiaggregants &amp; Statins &amp; Antihypertensives &amp; Bosentan</arm_group_label>
    <other_name>Tracleer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiaggregant therapy</intervention_name>
    <description>AAS 100mg/d or Clopidogrel 75mg/d</description>
    <arm_group_label>Antiaggregants &amp; Statins &amp; Antihypertensives &amp; Bosentan</arm_group_label>
    <arm_group_label>Antiaggregants &amp; Statins &amp; Antihypertensives</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Statins</intervention_name>
    <arm_group_label>Antiaggregants &amp; Statins &amp; Antihypertensives &amp; Bosentan</arm_group_label>
    <arm_group_label>Antiaggregants &amp; Statins &amp; Antihypertensives</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antihypertensive therapy</intervention_name>
    <arm_group_label>Antiaggregants &amp; Statins &amp; Antihypertensives &amp; Bosentan</arm_group_label>
    <arm_group_label>Antiaggregants &amp; Statins &amp; Antihypertensives</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Arterial hypertension and hypercholesterolemia

          -  ABI &lt;0,9

          -  Positive claudiometry with a claudication distance between 50 and 500

        Exclusion Criteria:

          -  surgical patient

          -  Previous revascularization procedure in the Member studied

          -  Smoker

          -  Uncontrolled hypertension

          -  Cardiac Stress Test unfinished

          -  Prior DVT

          -  Concomitant severe disease

          -  Obesity
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>De Haro Joaquin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de Getafe</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario de Getafe</name>
      <address>
        <city>Getafe</city>
        <state>Madrid</state>
        <zip>28901</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2012</study_first_submitted>
  <study_first_submitted_qc>November 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2012</study_first_posted>
  <last_update_submitted>November 28, 2012</last_update_submitted>
  <last_update_submitted_qc>November 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Getafe</investigator_affiliation>
    <investigator_full_name>Joaquin de Haro, M.D.</investigator_full_name>
    <investigator_title>Randomized controlled clinical trial of Bosentan in Intermittent Claudication in Peripheral Arterial Disease</investigator_title>
  </responsible_party>
  <keyword>Bosentan</keyword>
  <keyword>Peripheral Arterial Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Intermittent Claudication</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
    <mesh_term>Bosentan</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
    <mesh_term>Endothelin Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

